Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation

Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibition has revolutionized the treatment paradigm of urothelial carcinoma (UC). Several PD-L1 assays are conducted to formulate appropriate treatment decisions for PD-1/PD-L1 target therapy in UC. However, each assay has its o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyu Sang, Choe, Gheeyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pathologists and the Korean Society for Cytopathology 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141973/
https://www.ncbi.nlm.nih.gov/pubmed/33823566
http://dx.doi.org/10.4132/jptm.2021.02.22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141973/
https://www.ncbi.nlm.nih.gov/pubmed/33823566
http://dx.doi.org/10.4132/jptm.2021.02.22

Ejemplares similares